Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ).
Shanghai HeartCare Medical Technology Corporation Limited has called its 2025 annual general meeting for 28 May 2026 in Shanghai to review standard annual matters, including the 2025 board work report, profit distribution plan, audited financial statements, annual report and directors’ remuneration. Shareholders will also vote on reappointing Ernst & Young Hua Ming as domestic auditor and Ernst & Young as international auditor, as well as amendments to the procedural rules for the board and general meetings.
A key item on the agenda is a special resolution to grant the board a general mandate to issue additional H shares, domestic shares and unlisted foreign shares, and to sell or transfer treasury shares, up to 20% of each relevant share class. If approved, this mandate would give the company greater flexibility to raise capital and adjust its capital structure during the mandate period, potentially supporting future expansion while diluting existing holdings within the approved limits.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a China-based medical technology company listed in Hong Kong. It operates in the healthcare sector, focusing on innovative medical devices and related technologies, serving domestic and international markets through its H shares and various classes of domestic and unlisted foreign shares.
Average Trading Volume: 60,114
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$2.18B
See more data about 6609 stock on TipRanks’ Stock Analysis page.